Introduction
Hodgkin lymphoma (HL) in children and adolescents is cured in over 80% of cases using chemotherapy, with or without radiation therapy (RT). [1] [2] [3] With the exception of certain subgroups who might be cured with chemotherapy and/or RT, the treatment of refractory/relapsed disease often poses more of a challenge, although long-term survival rates have improved to 40-60% over the last 20 years with the use of high-dose chemotherapy (HDC) and auto-SCT. 2, 3 Most of the reported data describe an adult rather than a pediatric population, and the few reported pediatric series involve small numbers of patients. 2, [4] [5] [6] However, several studies suggest that the adult literature describing the use of auto-SCT in relapsed/refractory HL can be extrapolated to children and young adults. 1, 6 Numerous HDC regimens have been used before autologous stem cell rescue. 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] More commonly these regimens include CY, carmustine and etoposide, with or without cisplatin (CBV þ /ÀP) or BEAM. 7, 10, 13 The University of Calgary/Tom Baker Cancer Centre has used single-agent high-dose melphalan (HDM) as a local institutional protocol for over 20 years for adults with relapsed/refractory HL with comparable efficacy, reduced short-term morbidity and lower costs compared with more standard regimens. 8, 14 On the basis of the published results of HDM in the adult population at our institution showing comparable efficacy and a favorable toxicity profile when compared with other regimens, our pediatric blood and marrow transplant service has adopted this approach for children and adolescents with relapsed/refractory HL since 1996. Given the use of HDM followed by auto-SCT has not been described in children and adolescents with relapsed/ refractory HL, we felt that a review of our experience would provide novel information regarding the feasibility of this approach with some information regarding its efficacy as well.
Patients and methods

Study design
A retrospective analysis of all consecutive patients treated at Alberta Children's Hospital with HDM and auto-SCT between 1996 and 2009 for primary refractory and relapsed HL was carried out. All patients were to have histological confirmation of HL at initial presentation and were p18 years of age at the time HDM was given. Criteria to proceed to transplant included adequate cardiac function (ejection fraction X50%), pulmonary function (diffusion capacityX50%), hepatic function (aspartate aminotransferase/alanine aminotransferase o2.5 Â normal) and renal function (glomerular filtration rate X45 mL/min per 1.73 m 2 ). Those patients with localised recurrence believed to be curable with RT and/or chemotherapy were excluded. Patients were eligible for transplant if salvage chemotherapy achieved clinical or radiographic evidence of disease reduction. Informed consent for HDC and auto-SCT was obtained from all patients and/or parents. The institutional ethics review board approved this retrospective chart review.
Definitions
Relapsed disease was defined as disease progression in patients who had achieved a CR or a CR undetermined, with progression occurring at least 3 months after completion of initial therapy (chemotherapy and/or RT). Refractory disease was defined as failure to achieve a CR or CR undetermined with initial induction chemotherapy and/ or RT according to anatomic or functional imaging before the salvage therapy, or as disease progression within 3 months of completing standard initial induction chemotherapy and/or RT. Functional imaging included gallium and/or positron emission tomography scanning. Histological confirmation of disease relapse/progression was not required provided there was clear radiographic evidence of active disease.
Disease status before the transplant was assigned according to reporting definitions as per the Centre for International Blood and Marrow Transplant Research criteria and are as follows: a CR was defined as the absence of clinical or radiographic evidence of disease. A CR undetermined was defined as the absence of clinical evidence of disease with persistent scan abnormalities of unknown significance. A X50% reduction in the greatest diameter in all sites of known disease was considered a PR. No response/stable disease was defined as p50% reduction in greatest diameter in all sites of known disease. New sites of disease or an increase in size of known disease on treatment were considered progressive disease.
Bulk disease was defined as a nodal mass measuring 45 cm or widening of the mediastinum by 41/3. Staging was assigned as per the Ann Arbor classification. The total number of chemotherapy regimens was defined as the number of different chemotherapy combinations given pre-HDM.
HDC regimen
All patients received single-agent HDM, 200 mg/m 2 given i.v. on day À2. Stem cells were thawed and infused on day 0. Patients were hospitalised in a HEPA-filtered environment and standard supportive care measures were followed. Growth factor support consisting of G-CSF was later introduced as a standard supportive care medication.
Statistical methods
The primary objective was to determine the feasibility (that is, engraftment data and toxicity profile) of HDM and auto-SCT for relapsed/primary refractory HL. The proportion of patients with grade 3 or greater toxicities as per the Common Terminology Criteria for Adverse Effects, version 4.0 in the first 100 days post stem cell infusion were determined. Secondary objectives included OS, non-relapse mortality (NRM) and event-free survival. For event-free survival, we defined an event as relapse of HL/progression of disease after HDM and auto-SCT or death from any cause.
Results
Patient characteristics
Characteristics for the eight identified patients are listed in Table 1 . The median age at the time of transplantion was 16 years, 10 months. Mobilised PBSCs were used for rescue in all patients with a median cell dose of 5.0 Â 10 6 CD34 þ cells/kg (1.9-11.3). Six of eight patients received vinorelbine and ifosfamide for cytoreduction pre-transplant. Those patients who had not already received RT before HDM and auto-SCT were given RT on recovery from megatherapy, around day þ 100.
Hematological engraftment
The median time to neutrophil engraftment (ANC X0.5 Â 10 9 /L for 3 consecutive days) was 12 days (range, 10 to 14 days). Platelet engraftment (platelet count X20 Â 10 9 /L with no transfusion during the 7 days before) occurred at a median of 19 days (range, 10-27 days). G-CSF was given to six of eight patients.
Toxicity
All patients developed grade 4 hematological toxicity. Three of eight patients had an infectious complication grade 3 or greater (two grade 3 and one grade 4). The grade 4 infectious complication involved fever, neutropenia, hypotension and pneumonia. Grade 3 mucositis was seen in three of eight patients. No other toxicities grade 3 or greater were noted, with no pulmonary or cardiac toxicities documented. Patient 7 has ongoing grade 1 chronic renal disease (proteinuria). No secondary malignancies have been identified to date.
Survival and relapse data
At day 100 post-auto-SCT all patients were alive and none had evidence of disease. With a median follow-up of 44 months (18-175), two of the eight patients had a second relapse (Table 1) . Patient 5 is currently in CR3 post-allo-SCT. Six patients remain in remission with a median follow-up of 54 months .
Discussion
Pediatric HL is most often cured with upfront chemotherapy and/or RT, with relapsed and primary refractory disease having been shown to be more difficult to treat. [2] [3] [4] 6 More commonly used conditioning regimens in adults and children have achieved event-free survival rates between 40 and 60%. 2, [4] [5] [6] 10, 12, 15 Although the NRM for those with HL treated with auto-SCT has decreased with time, the use of HDC with or without RT is not without toxicity. The NRM with CBV þ /ÀP has been reported between 23 and 26%, and when second malignancies are excluded, has been reported between 5 and 14%. 12, 13, 16 Baker et al. 2 reported on their experience in children and adolescents, and although this paper covers a different transplant era, the NRM rate was 9/53. Most of the patients in this series received CBV. Published European registry data indicated an NRM rate of 11.1% for 81 pediatric patients who underwent auto-SCT for HL before 1993. 6 Interstitial pneumonitis was an important cause of death in this series. Many authors believe that with current supportive care and the use of PBSCs, early NRM rates are closer to 5%. 12, 17, [18] [19] [20] At our institution, no early NRM using HDM as conditioning before auto-SCT for HL in adults was reported, and there have been no treatment-related deaths in our pediatric series. 8, 14 Numerous publications emphasise the many toxicities which can be seen in patients who undergo HDC and auto-SCT for HL. The European series of 81 pediatric patients referenced above described interstitial pneumonitis (6/81), fungal infections (5/81), cardiac complications (4/81) and veno-occlusive disease (5/81). 6 Reece et al. 7 also reported idiopathic interstitial pneumonitis as a significant nonhematological toxicity in 9/58 who received CBV or CBV þ /ÀP conditioning, and in another series report rates of pulmonary toxicity between 21 and 24%. 7, 12 The toxicities seen in our eight patients were considered acceptable, and are comparable to those published for BEAM conditioning. 9, 17 No secondary malignancies in our cohort have been noted to date, although longer follow-up is required. Mucositis, myelosuppression and infections were the most common toxicities seen. In contrast to the CBV þ /ÀP and BEAM data we saw no pulmonary toxicity, with six of eight patients having received radiotherapy pre-transplant, although our series was small. The adult experience with HDM was similar, with no Bearman grade III regimen-related toxicity seen in 46 patients. 14 Our engraftment data were comparable with those previously published for auto-SCT in HL. 4, 6, 7, 17 We consider the duration of follow-up of this cohort with HL to be adequate to comment on feasibility.
Our study was clearly not powered to make any meaningful comment on overall and progression-free survival. Our group did mandate some evidence of chemosensitivity before receiving HDM and auto-SCT, in contrast to many other published reports, which may have biased our results towards better outcomes. 4, 6, 7, 12, 14, 17 However, a review of our institutional registry from 1991 to 2009 revealed that no patient was ineligible for HDC because of the suboptimal response to salvage chemotherapy. The single patient in our series with stable disease pretransplant did have radiographic evidence of reduction in disease, but did not constitute a PR. Only two patients had initial remissions longer than 12 months, with only one patient having an initial remission greater than 15 months. Clearly this was a high risk cohort of patients.
In summary, single-agent HDM in pediatric patients with relapsed or refractory HL is feasible as evidenced by our engraftment and toxicity data. This regimen spares patients from additional agents which have well-described toxicities. 6, 7, 12, 13, 17 In addition to published adult data, our small series suggests that this regimen should be explored further in the pediatric setting, with the goal of demonstrating comparable rates of disease control while reducing toxicity. Comprehensive follow-up data of greater duration will be essential.
